N/A
N=86
Comparison of Repetitive Magnetic Stimulation and Exercise on Quadriceps Function in COPD
Chronic Obstructive Pulmonary Disease
Bottom Line
View on ClinicalTrials.gov: NCT00737698 ↗Enrolled (actual)
86
Serious AEs
0.0%
Results posted
Sep 2019
Primary outcome: Primary: Quadriceps Fibre Size of Type IIa Fibres — 3885; 4326; 3610 micrometers squared
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Exercise (Other); Repetitive magnetic stimulation (Other)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- Imperial College London
- Primary completion
- Oct 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Quadriceps Fibre Size of Type IIa Fibres |
3885; 4326; 3610 | — |
Summary
Background Chronic Obstructive Pulmonary Disease (COPD) patients develop leg weakness and a reduced walking capacity, due to reduced leg muscle oxygen-utilising capacity (OUC). Animal experiments indicate that low muscle levels of Peroxisome Proliferator-Activated Receptors (PPAR) cause the reduced muscle OUC.
Aims
In COPD patients, investigate whether:
1. reduced muscle PPAR levels cause reduced leg muscle OUC, by investigating a correlation between these in muscle samples (Study 1).
2. training increases muscle PPAR levels in proportion to increases in OUC, as should occur if PPARs control OUC (Study 2).
3. muscle PPAR levels and walking capacity correlate (Study 1 and 2).
3. the new technique of repetitive stimulation of the nerve to the leg with a magnet (rMS) improves muscle OUC (Study 2).
Study 1 Leg weakness and walking ability are assessed in 75 patients, then a leg muscle sample is taken to measure PPARs and OUC.
Study 2 60 Study 1 patients have either cardiovascular training, rMS, or no training, for 8 weeks, then are re-studied as in Study 1.
Importance If reduced PPAR levels correspond with leg weakness, medicines can be developed to target these receptors and treat weakness. If rMS is effective, it can be offered to patients.
Eligibility Criteria
Inclusion Criteria
- Chronic Obstructive Pulmonary Disease
Exclusion Criteria
- Cardiac failure
- Renal failure
- Liver failure
- Diabetes mellitus
- Systemic inflammatory diseases eg Rheumatoid arthritis, SLE
- Warfarin, coagulation problems
Data sourced from ClinicalTrials.gov (NCT00737698). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.